Vanguard Group Inc Sellas Life Sciences Group, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,292,857 shares of SLS stock, worth $2.27 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,292,857
Previous 1,786,334
28.36%
Holding current value
$2.27 Million
Previous $2.13 Million
34.87%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding SLS
# of Institutions
39Shares Held
5.69MCall Options Held
1.67MPut Options Held
74.7K-
Anson Funds Management LP Dallas, TX794KShares$785,8960.12% of portfolio
-
Geode Capital Management, LLC Boston, MA605KShares$599,1390.0% of portfolio
-
Black Rock Inc. New York, NY430KShares$426,0640.0% of portfolio
-
Empery Asset Management, LP New York, NY308KShares$305,3813.71% of portfolio
-
Opus Capital Group, LLC226KShares$223,8390.04% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $20.3M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...